Rethinking Dysautonomia: Beyond the Autonomic Nervous System – Towards a Systems-Level Perspective7/21/2025 Abstract Dysautonomia is currently described as an umbrella term for a variety of medical conditions involving dysfunction of the autonomic nervous system (ANS). The ANS is known to regulate numerous involuntary physiological processes such as heart rate, blood pressure, digestion, pupil dilation, kidney function, and thermoregulation. However, these functions do not occur through isolated ANS activity; they depend on dynamic interactions with other autonomic regulatory systems, notably the central autonomic network, the neuroendocrine system, and the immune–inflammatory system. Given this inherent interconnectedness, it is scientifically insufficient and clinically limiting to reduce dysautonomia exclusively to ANS dysfunction. This is especially the case to explain the full spectrum of stress-related physiological disorders where such reductionism fosters diagnostic fragmentation and therapeutic inefficiency. Drawing from clinical experience and current scientific literature, this paper argues for reframing dysautonomia as a systemic regulatory failure within the Extended Autonomic Regulatory System – to better reflect the complex pathophysiology of dysautonomic conditions seen in practice. Background Dysautonomia is currently described as an abnormality in the function of the autonomic nervous system (ANS) (Reichgott, 1990), encompassing a wide range of clinical manifestations including musculoskeletal disorders, respiratory difficulties, heart palpitations, chest discomfort, digestive dysfunction, lightheadedness, and nausea, among others. However, viewing these processes exclusively through the lens of ANS dysfunction neglects their integration within broader regulatory frameworks, notably the central autonomic network (CAN), the neuroendocrine system (NE-S), and the immune–inflammatory system (IIS). Because the ANS does not function independently of these systems, limiting the conceptualisation of dysautonomia solely to the ANS undermines both diagnostic accuracy and therapeutic effectiveness. Clinically complex, multisystemic presentations frequently lead to mismatches in diagnosis and treatment. For instance, a patient presenting with the previously mentioned ANS-related symptoms – alongside additional issues such as brain fog, cognitive decline, insomnia, hormonal imbalances, and muscle or joint aches – often fails to meet traditional ANS-centric diagnostic criteria for dysautonomia. Yet, when assessed through the broader autonomic regulatory framework that incorporates the CAN, NE-S, and IIS, such presentations clearly fit within the scope of dysautonomia. Treatment strategies designed within this expanded autonomic perspective consistently yield improved and accelerated patient outcomes. Conversely, focusing solely on ANS-related symptoms and separately addressing additional manifestations – such as cognitive decline through psychopharmacology and psychotherapy – typically results in limited efficacy, symptom exacerbation, and the emergence of additional symptoms over time. Consequently, redefining dysautonomia as a systemic regulatory disorder encompassing multiple interdependent physiological systems will enhance diagnostic accuracy, facilitate targeted treatments, and improve overall patient outcomes. Adopting this systemic approach promises faster patient recovery and significant cost reductions for healthcare systems.
Current Research Paradigm and Limitations Contemporary dysautonomia research remains predominantly neurocentric, with a strong emphasis on ANS biomarkers such as heart rate variability, baroreflex sensitivity, and vagal tone, and interventions targeting these markers. Although these biomarkers and interventions have clinical significance, their isolated application neglects the broader systemic interactions integral to ANS function. Consequently, this limited perspective inadequately addresses the complex multisystem dysregulation commonly observed in clinical practice. Authors Note: The term dysautonomia is derived from three component parts: dys‑, from the Ancient Greek δυσ‑, meaning bad, difficult, or impaired; autonomic, from Greek αὐτόνομος (autonomos), meaning self-governing; and the suffix ‑ia, indicating a state or condition. Collectively, these components mean a disorder of self-governance. Self-governance, however, is not solely related to the ANS. Thus, why dysautonomia is narrowly defined as referring exclusively to abnormalities in the function of the ANS remains unclear to me. Complex clinical presentations characterised by multiple unexplained symptoms, such as persistent fatigue, cognitive impairment, diffuse musculoskeletal pain, and other hallmark features frequently observed (but not exclusively) in long COVID, highlight significant gaps in current diagnostic and therapeutic approaches. Patients presenting multisystemic patterns are often misdiagnosed or unjustly categorised as psychosomatic. While these symptoms can, if observed within the EARS, clearly have a biological basis. In my practice, I frequently encounter patients who are referred to psychologists when medical examinations and diagnostic tests yield inconclusive results. One other common recommendation is to try vagal stimulation, as the reductionist approach suggests that certain symptoms may be associated with the imbalance between sympathetic and parasympathetic activity. Restoring the balance through stimulating vagal activity is then the rationale. However, in my experience – listening closely to patients – vagal stimulation has often led to a worsening of symptoms in nearly all who have tried it. I believe this is because isolated vagal stimulation does not necessarily result in sympathetic downregulation. As a result, both sympathetic and parasympathetic activity can become simultaneously upregulated. This observation has reinforced my belief that narrowing dysautonomia to solely the autonomic nervous system is an inappropriate approach. Such a narrow definition often leads to treatment mismatches, resulting in paradoxical autonomic responses and exacerbating systemic dysregulation rather than alleviating symptoms. Furthermore, the fact is that the ANS does not function in isolation; it operates under the regulatory influence of the CAN, the NE-S, and the IIS. Therapeutic approaches that disregard these broader regulatory interactions frequently result in suboptimal or counterproductive outcomes. In summary, the principal limitations of the current dysautonomia research paradigm include:
The Extended Autonomic Regulatory System Recent efforts to broaden the understanding of autonomic regulation have emerged, notably Goldstein's "Extended Autonomic System" (2021, 2024). Building upon and refining these foundations, I introduce the concept of the Extended Autonomic Regulatory System to highlight the necessity of systemic regulatory coherence rather than isolated nerve signalling. EARS comprises:
Dysautonomia as Multi-System Dysregulation Patients frequently present with sudden-onset musculoskeletal pain or depression like symptoms or general malaise without clear triggers. These symptoms often coexist with insomnia or fragmented sleep, heart palpitations or fluttering sensations disconnection from self, gastrointestinal disturbances, fatigue or low energy, hormonal imbalances, unexplained (low-grade) fevers, bloating, wondering symptoms, flare-ups or relapses. Seemingly these symptoms seem unrelated and often put down to stress seen some of the symptoms. Diagnosis done stress is then in itself narrowed to the ANS. The ANS does’t explain all the symptoms but a let’s see attitude is often seen or treated separately with prescribed rest, medication and psychotherapy. While seen from the broader EARS model all can be related and diagnosed and treated accordingly not as separate symptoms but as symptoms with one origin that probably is stress-related. Clinical Implications and the Reaset Approach Recognising systemic dysregulation necessitates interventions capable of restoring coherent regulatory interactions across the EARS. The Reaset Approach exemplifies such a systems-level therapeutic model, employing body-centred, sensory-based techniques to facilitate systemic regulation. This approach does not require precise localisation of dysfunction but aims to recalibrate overall system coherence. Clinically, patients with functional dysautonomia frequently respond positively within one or two sessions, provided no structural lesion has developed. Functional Dysautonomia vs. Autonomic Lesion A critical distinction must be acknowledged:
Future Directions for Research The EARS model opens several avenues for future interdisciplinary investigation: Detailed mapping of interactions among EARS components in various dysautonomic conditions. Identification of robust biomarkers indicative of systemic dysregulation. Systematic assessment of therapeutic interventions (manual therapy, lifestyle modification, pharmacological agents) on systemic regulatory coherence. Such research promises not only more effective interventions but also deeper insights into the fundamental mechanisms underlying systemic adaptive processes. Conclusion To address the growing burden of dysautonomic conditions effectively, we must transition from a neurocentric model towards a comprehensive, systems-level understanding. The EARS framework articulated here offers a robust conceptual foundation for future research, diagnosis, and treatment, aligning clinical practice with physiological complexity. This evolution is imperative, scientifically justified, and ethically necessary in an era of increasingly prevalent stress-related disorders. References
This article was written by Tom Meyers with the assistance of ChatGPT, blending personal insights and advanced AI support to create a compelling and impactful message.
0 Comments
Leave a Reply. |
RSS Feed
